Overview

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Status:
Active, not recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants including the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Norethindrone
Norethindrone Acetate
Polyestradiol phosphate